Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. The firm is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
Follow-Up Questions
Haemonetics Corp (HAE)의 PER은 얼마입니까?
Haemonetics Corp의 PER은 14.4406입니다
Haemonetics Corp의 CEO는 누구입니까?
Mr. Christopher Simon은 2016부터 회사에 합류한 Haemonetics Corp의 President입니다.
HAE 주식의 가격 성능은 어떻습니까?
HAE의 현재 가격은 $50.26이며, 전 거래일에 decreased 0% 하였습니다.
Haemonetics Corp의 주요 사업 주제나 업종은 무엇입니까?
Haemonetics Corp은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Haemonetics Corp의 시가총액은 얼마입니까?
Haemonetics Corp의 현재 시가총액은 $2.4B입니다
Haemonetics Corp는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 12명의 분석가가 Haemonetics Corp에 대한 분석 평가를 실시했으며, 이는 5명의 강력한 매수, 7명의 매수, 2명의 보유, 1명의 매도, 그리고 5명의 강력한 매도를 포함합니다